AC Immune (ACIU -15.5%) is flirting with a complete round trip from Friday's almost 24% jump. Shares perked up on Friday after the company announced a data presentation by collaboration partner Genentech (OTCQX:RHHBY) late Friday afternoon. The data, supporting the rationale and early clinical results of lead product candidate crenezumab, were presented at the CTAD meeting in San Diego. The company says data from an exposure-response model predict an improved outcome of the Phase 3 CREAD study in patients with prodromal-to-mild Alzheimer's disease.
Investors cooled off considerably today when, apparently, realism set in about the expected 2020 read-out for top-line results from CREAD.
Crenezumab is a fully humanized IgG4 monoclonal antibody that binds to all forms of misfolded Abeta proteins, especially Abeta oligomers, to prevent and break up Abeta aggregation and promote Abeta disaggregation. Tau and beta amyloid (Abeta) are associated with neurodegeneration. Tangles and aggregations in the brain characterize Alzheimer's disease.
Subscribe for full text news in your inbox